New asthma inhaler passes first safety check in small study

NCT ID NCT06385964

First seen Mar 26, 2026 · Last updated Jun 22, 2026 · Updated 11 times

Summary

This early-stage trial tested an experimental inhaled drug called SHR-4597 in 62 people: healthy volunteers and asthma patients. The main goal was to check if the drug is safe and tolerable when inhaled as a dry powder. Researchers gave single or multiple doses and watched for side effects. This study does not yet tell us if the drug works for asthma, only that it was safe enough to continue testing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, 200433, China

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SHR-4597 (an experimental drug taken by inhaling a dry powder)

What this could lead to

If safe, this could lead to a new inhaled treatment option for asthma that helps control symptoms.

What could go wrong

This is a very early Phase 1 trial focused only on safety and dosing. It is too small and short to know if the drug actually helps asthma. Many early-stage drugs fail to show benefit in later trials.

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.